Artículos por temáticas

Levodopa and nutrition support: A case report of Parkinsonism-hyperpyrexia syndrome

Burslem R, Ramos L, Chou C, Szlufman C, Ziegler J.

Nutr Clin Pract. 2025 Oct;40(5):1225-1229. doi: 10.1002/ncp.11297. Epub 2025 Apr 13.

Editorial: Cell death mechanisms in neurodegenerative disorders

Tare M, D'Orsi B, Singh A.

Front Cell Dev Biol. 2025 Oct 9;13:1694173. doi: 10.3389/fcell.2025.1694173. eCollection 2025.

The application of telmisartan in central nervous system disorders

Quan W, Zhang SX, Zhang XY, Chen X, Yang C, Li ZY, Hu R.

Pharmacol Rep. 2025 Oct;77(5):1196-1216. doi: 10.1007/s43440-025-00737-2. Epub 2025 Jun 19.

Characterizing resting-state EEG oscillatory and aperiodic activity in neurodegenerative diseases: A multicentric study

Jaramillo-Jimenez A, Mantilla-Ramos YJ, Tovar-Rios DA, Lopera F, Aguillón D, Ochoa-Gomez JF, Paquet C, Gaubert S, Pardini M, Arnaldi D, Taylor JP, Fladby T, Brønnick K, Aarsland D, Bonanni L; E-DLB Co

Comput Biol Med. 2025 Oct;197(Pt B):111080. doi: 10.1016/j.compbiomed.2025.111080. Epub 2025 Sep 17.

Neurotoxicity associated with chimeric antigen receptor T-cell therapy

Wronski M, Wesselingh R, Kazzi C, Seery N, Ko K, Li J, Tan TH, Simpson T, Abbott C, Fleming S, Inam S, Tam CS, Wong SM, O'Brien T, van der Walt A, Spencer A, Butzkueven H, Monif M.

J Neuroimmunol. 2025 Oct 15;407:578717. doi: 10.1016/j.jneuroim.2025.578717. Epub 2025 Aug 9.

Dopaminergic signalling in gastrointestinal health and disease

Pasricha TS, Kulkarni S.

Nat Rev Gastroenterol Hepatol. 2025 Oct;22(10):696-707. doi: 10.1038/s41575-025-01112-5. Epub 2025 Sep 8.

Gene and RNA Editing: Revolutionary Approaches to Treating Diseases

Li JM, Huang J, Liao Y, Hu T, Wang CL, Zhang WZ, Huang CW.

MedComm (2020). 2025 Oct 13;6(10):e70389. doi: 10.1002/mco2.70389. eCollection 2025 Oct.

Dystonia-predominant VPS35-related parkinson's disease: diagnostic challenges and the role of Levodopa response in unmasking genetic etiology

Tan C, Yang J, Yang Q, Feng X.

Neurol Sci. 2025 Oct;46(10):5479-5480. doi: 10.1007/s10072-025-08437-8. Epub 2025 Aug 26.

A Variant of OTUD3 in Early-Onset Parkinsonism

Ahmad SR, Nasir N, Kumari A, Hassan AU.

Neuropathol Appl Neurobiol. 2025 Oct;51(5):e70046. doi: 10.1111/nan.70046.

Unveiling Butyrate as a Parkinson's Disease Therapy

Abreu AE, Empadinhas N, Cardoso SM.

Neurosci Bull. 2025 Oct 15. doi: 10.1007/s12264-025-01498-x. Online ahead of print.

Neurotransmitters in Neural Circuits and Neurological Diseases

Gholami A, Mortezaee K.

ACS Chem Neurosci. 2025 Oct 1;16(19):3653-3664. doi: 10.1021/acschemneuro.5c00426. Epub 2025 Sep 17.

Emerging roles of Midnolin in Cancer, Parkinson's Disease, and Metabolic dysfunction

Kalyan M, Singh PK, Verma A.

Mol Biol Rep. 2025 Oct 13;52(1):1022. doi: 10.1007/s11033-025-11120-y.

New insights into axonal regulators of dopamine transmission in health and disease

Todd KL, Cramb KML, Brimblecombe KR, Cragg SJ.

Curr Opin Neurobiol. 2025 Oct;94:103093. doi: 10.1016/j.conb.2025.103093. Epub 2025 Aug 16.

Can Intrinsic Capacity Help Identify Those at Risk of Parkinson Disease?

Persico M, Esper CD.

Neurology. 2025 Oct 21;105(8):e214242. doi: 10.1212/WNL.0000000000214242. Epub 2025 Sep 22.

The Mitochondrial-Astrocyte-Neuron Triad Hypothesis in Parkinson's Disease: A Toxic Feedback Loop of Metabolism, Aggregation, and Oxidative Stress

Walecha V, Luthra PM.

Neurochem Res. 2025 Oct 4;50(5):317. doi: 10.1007/s11064-025-04559-9.